

Novartis data demonstrates consistent efficacy and tolerability of Kisqali® combination therapy in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visceral disease

Dec 08, 2018

Source URL: <https://qa1.novartis.us/news/media-releases/novartis-data-demonstrates-consistent-efficacy-and-tolerability-kisqali-combination-therapy-hrher2-advanced-breast-cancer-patients-difficult-treat-visceral-disease-0>

List of links present in page

1. <https://qa1.novartis.us/news/media-releases/novartis-data-demonstrates-consistent-efficacy-and-tolerability-kisqali-combination-therapy-hrher2-advanced-breast-cancer-patients-difficult-treat-visceral-disease-0>